Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Allen Wolstenholme"'
Autor:
Hardik Chandasana, Ryan Marnoch, Michael McKenna, Julia Double, Ciara Seal, Gilda Bontempo, Allen Wolstenholme, Ann Buchanan
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1470 (2023)
This randomized food effect study in healthy adult participants examined dispersible tablet formulations of fixed-dose combinations of dolutegravir/abacavir/lamivudine (TRIUMEQ) and dolutegravir/lamivudine (DOVATO). While adult tablet formulations of
Externí odkaz:
https://doaj.org/article/7d722b13cd6d4956bb3679defaecc722
Autor:
Rajendra P. Singh, Kimberly K. Adkison, Mark Baker, Ridhi Parasrampuria, Allen Wolstenholme, Mark Davies, Nicola Sewell, Cindy Brothers, Ann M. Buchanan
Publikováno v:
Pediatric Infectious Disease Journal. 41:230-237
BACKGROUND The World Health Organization (WHO) 2019 antiretroviral treatment guidelines recommend use of optimal treatment regimens in all populations. Dolutegravir-based regimens are the preferred first-line and second-line treatment in infants and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27c626f13f1a4d7fffbb57b61580db0
https://doi.org/10.1097/inf.0000000000003366
https://doi.org/10.1097/inf.0000000000003366
Autor:
Mark Krystal, Shiven Chabria, Daren Austin, Allen Wolstenholme, David Wensel, Max Lataillade, Judah Abberbock, Mark Baker, Peter Ackerman
Publikováno v:
Antiviral therapy. 27(5)
Background The GSK3732394 multivalent protein was developed as a novel, long-acting, antiretroviral biologic treatment regimen with three independent, non–cross-resistant mechanisms for inhibiting HIV-1 entry. Methods A single-centre, Phase 1, doub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d58925f49dfe9e3146003dd402152676
https://pubmed.ncbi.nlm.nih.gov/36191080
https://pubmed.ncbi.nlm.nih.gov/36191080
Publikováno v:
Clinical Pharmacology in Drug Development
Pharmacokinetics, safety, and tolerability of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg were assessed in this phase 1, single‐arm, open‐label, single‐dose study in fasted healthy male (n = 4) and female (n = 8) participants of Japane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbd0b3d9bc18c93fa942fd1b739bba0
https://doi.org/10.1002/cpdd.996
https://doi.org/10.1002/cpdd.996
Autor:
Allen Wolstenholme, Joseph A. Piscitelli, Herta Crauwels, Rashmi Mehta, Kimberly K. Adkison, Caifeng Fu, Brian Wynne
Publikováno v:
Clinical Pharmacology: Advances and Applications. 12:49-52
Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. A 2-part study evaluated the relative bioavailability and food effect of five experimental fixed-dose co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::442b5f65cc83dfa361a1d5fe6bdb9955
https://doi.org/10.2147/cpaa.s250751
https://doi.org/10.2147/cpaa.s250751
Autor:
Allen Wolstenholme, Sherif El-Harazi, Jyoti Patel, Scott Rasmussen, John T. Thompson, Justin A. Green, Alex Yuan, Azra Hussaini, Jason S. Slakter, David E. Barañano, Alessandro Berni, Gavin C. K. W. Koh, Elizabeth Hardaker, Deborah S. Kelly, Hakop Gevorkyan, John Tonkyn, Hanna Coleman, Keith A. Warren, Siôn W. Jones, Stephan Duparc, Khadeeja Mohamed, Robert C. Sergott, Jessica Ackert
Publikováno v:
Drug Safety
Introduction Tafenoquine has been recently registered for the prevention of relapse in Plasmodium vivax malaria. Objective This study assessed the pharmacodynamic effects of 300-mg single-dose tafenoquine on the retina. Methods This phase I, prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb195b877c87d0493e508869a9ec61c5
https://doi.org/10.1007/s40264-019-00839-w
https://doi.org/10.1007/s40264-019-00839-w
Autor:
Zhiping Zhang, Amy Eld, Teodora Perger, Kimberly K. Adkison, Harald Vangerow, Mark S. Shaefer, Allen Wolstenholme, Yu Lou, Cynthia McCoig, Katy Hayward
Publikováno v:
Clinical Pharmacology and Therapeutics
In children aged ≤4 years, the relative bioavailability of lamivudine oral solution was 37% lower than that of a tablet formulation. An open‐label, four‐way crossover study was conducted in healthy adults to evaluate the effect of sorbitol, a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c674ba678d4c725a9c5d6bf1fc9e95aa
https://doi.org/10.1002/cpt.943
https://doi.org/10.1002/cpt.943
Autor:
Naomi Givens, Kimberly K. Adkison, Caifeng Fu, Herta Crauwels, Kristin Di Lullo, Rashmi Mehta, Simon Vanveggel, Shashidhar Joshi, Allen Wolstenholme, Brian Wynne
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
A complete 2-drug regimen of dolutegravir at 50 mg and rilpivirine at 25 mg was approved to treat HIV-1 infection in virologically suppressed patients after demonstrating acceptable efficacy and tolerability. This study investigated the bioequivalenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197ac7a3ea5eac3b81cb26ce17e1855d
https://doi.org/10.1128/aac.00748-18
https://doi.org/10.1128/aac.00748-18
Publikováno v:
Advances in Therapy. 32:157-171
A combination of fluticasone furoate (FF) and umeclidinium (UMEC) has been considered for development for the treatment of asthma. The primary objectives were to investigate the plasma and urine pharmacokinetics (PK) of FF/UMEC in combination compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4225fe8d234ecbba0562bac7937c3cd
https://doi.org/10.1007/s12325-015-0184-6
https://doi.org/10.1007/s12325-015-0184-6
Autor:
Lauren E. Richards-Peterson, Tarjinder Sahota, Peter J. Gough, Sujith Madhavan, Kat Povey, Michael Reilly, J. Gene Wang, Allen Wolstenholme, Mei-Lun Wang, Bartholomew J. Votta, John D. Lich, Joshua N. Finger, Kathleen M. Weisel, Todd Rudo, Nicola Scott, Monica Simeoni, Debra J. Tompson, Adeline Verticelli, John Bertin, Philip A. Harris
Publikováno v:
Pharmacology Research & Perspectives
GSK2982772 is a highly selective inhibitor of receptor‐interacting protein kinase 1 (RIPK1) being developed to treat chronic inflammatory diseases. This first‐in‐human study evaluated safety, tolerability, pharmacokinetics (PK), and exploratory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1017f88919e51ac2e24deda9721b129e
http://europepmc.org/articles/PMC5723699
http://europepmc.org/articles/PMC5723699